Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;27(5):463-466.
doi: 10.5863/1551-6776-27.5.463. Epub 2022 Jul 6.

Rechallenge of Elexacaftor/Tezacaftor/Ivacaftor After Skin Rash in Two Pediatric Patients

Emily R Diseroad  1   2 , Peter J Mogayzel Jr  3 , Alice Pan  2
Affiliations

Rechallenge of Elexacaftor/Tezacaftor/Ivacaftor After Skin Rash in Two Pediatric Patients

Emily R Diseroad et al. J Pediatr Pharmacol Ther. 2022.

Abstract

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have revolutionized care for patients with cystic fibrosis (CF). The triple combination product elexacaftor/tezacaftor/ivacaftor is a highly effective CFTR modulator that is generally well tolerated. However, in clinical trials of pediatric and adult patients, 4% to 12% developed rash after initiation of therapy. Few reports have described approaches to management of this adverse effect. In this report, we describe 2 children with CF who developed a pruritic, maculopapular rash after initiating elexacaftor/tezacaftor/ivacaftor. These patients were successfully rechallenged after rash resolution with a practical titration schedule.

Keywords: CFTR modulator; cystic fibrosis; rash.

PubMed Disclaimer

Conflict of interest statement

Disclosures. The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment gifts, and honoraria. PJM receives grant support from the Cystic Fibrosis Foundation, Eloxx, and Vertex Pharmaceuticals. Authors had full access to all patient information in this report and take responsibility for the integrity and accuracy of the report.

Figures

Image 1.
Image 1.
(a) Left palm and (b) lower back of case 1 on first day of elexacaftor/tezacaftor/ivacaftor therapy.
Image 2.
Image 2.
(a) Left hand and (b) left foot of case 2 on eighth day of elexacaftor/tezacaftor/ivacaftor therapy.
See this image and copyright information in PMC

References

    1. Middleton PG, Mall MA, Dřevínek P et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe-508del allele. N Engl J Med . 2019;381(19):1809–1819. - PMC - PubMed
    1. Heijerman HGM, McKone EF, Downey DG et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet . 2019;394(10212):1940–1948. - PMC - PubMed
    1. Zemanick E, Taylor-Cousar J, Davies J et al. A phase 3 open-label study of ELX/TEZ/IVA in children 6 through 11 years of age with CF and at least one F508del allele. Am J Respir Crit Care Med . 2021;203(12):1522–1532. - PMC - PubMed
    1. Boston, MA: Vertex Pharmaceuticals Inc; Oct, 2021. TRIKAFTA (elexacaftor, tezacaftor and ivacaftor tablets) [package insert]
    1. Hu MK, Wood G, Dempsey O. “Triple therapy” (elexacaftor, tezacaftor, ivacaftor) skin rash in patients with cystic fibrosis. Postgrad Med J . 2022;98(1156):86. - PubMed

LinkOut - more resources